SUM102PTHomo sapiens (Human)Cancer cell line
Also known as: 102PT, Sum102, SUM102, SUM 102, SUM-102, SUM 102PT, SUM-102PT
Quick Overview
SUM102PT is a human breast cancer cell line derived from an intraductal carcinoma with micro-invasion, used in cancer research.
Detailed Summary
Research Applications
Key Characteristics
Basic Information
| Database ID | CVCL_3421 |
|---|---|
| Species | Homo sapiens (Human) |
| Tissue Source | Breast[UBERON:UBERON_0000310] |
Donor Information
| Age | 57 |
|---|---|
| Age Category | Adult |
| Sex | Female |
| Subtype Features | TNBC |
Disease Information
| Disease | Breast carcinoma |
|---|---|
| Lineage | Breast |
| Subtype | Breast Invasive Ductal Carcinoma |
| OncoTree Code | IDC |
DepMap Information
| Source Type | Asterand |
|---|---|
| Source ID | ACH-001388_source |
Known Sequence Variations
| Type | Gene/Protein | Description | Zygosity | Note | Source |
|---|---|---|---|---|---|
| MutationSimple | PIK3CA | p.His1047Arg (c.3140A>G) | Unspecified | - | PubMed=25926053, PubMed=20570890 |
| Gene deletion | CDKN2A | - | Homozygous | Possible | PubMed=26870271 |
Haplotype Information (STR Profile)
Short Tandem Repeat (STR) profile for cell line authentication.
Loading gene expression data...
Publications
Development and implementation of the SUM breast cancer cell line functional genomics knowledge base.
Duchinski K., Couch D., Gray J.W., Kappler C.S.
NPJ Breast Cancer 6:30.1-30.14(2020).
Modeling precision treatment of breast cancer.";
Collisson E.A., van 't Veer L.J., Spellman P.T., Gray J.W.
Genome Biol. 14:R110.1-R110.14(2013).
Characterization of cell lines derived from breast cancers and normal mammary tissues for the study of the intrinsic molecular subtypes.
Harrell J.C., Roman E., Adamo B., Troester M.A., Perou C.M.
Breast Cancer Res. Treat. 142:237-255(2013).
miRNA expression profiling of 51 human breast cancer cell lines reveals subtype and driver mutation-specific miRNAs.
Martens J.W.M.
Breast Cancer Res. 15:R33.1-R33.17(2013).
Phenotypic and molecular characterization of MCF10DCIS and SUM breast cancer cell lines.
Barnabas N., Cohen D.
Int. J. Breast Cancer 2013:872743.1-872743.16(2013).
Triple negative breast cancer cell lines: one tool in the search for better treatment of triple negative breast cancer.
Chavez K.J., Garimella S.V., Lipkowitz S.
Breast Dis. 32:35-48(2010).
Distinct gene mutation profiles among luminal-type and basal-type breast cancer cell lines.
den Bakker M.A., Foekens J.A., Martens J.W.M., Schutte M.
Breast Cancer Res. Treat. 121:53-64(2010).
Molecular profiling of breast cancer cell lines defines relevant tumor models and provides a resource for cancer gene discovery.
Pollack J.R.
PLoS ONE 4:E6146-E6146(2009).
Thirteen new p53 gene mutants identified among 41 human breast cancer cell lines.
Wasielewski M., Elstrodt F., Klijn J.G.M., Berns E.M.J.J., Schutte M.
Breast Cancer Res. Treat. 99:97-101(2006).
BRCA1 mutation analysis of 41 human breast cancer cell lines reveals three new deleterious mutants.
van den Ouweland A.M.W., Merajver S.D., Ethier S.P., Schutte M.
Cancer Res. 66:41-45(2006).
Evidence that both genetic instability and selection contribute to the accumulation of chromosome alterations in cancer.
Edwards P.A.W., Caldas C.
Carcinogenesis 26:923-930(2005).
Comparative genomic hybridization analysis of 38 breast cancer cell lines: a basis for interpreting complementary DNA microarray data.
Gooden G.C., Ethier S.P., Kallioniemi A.H., Kallioniemi O.-P.
Cancer Res. 60:4519-4525(2000).
Molecular cytogenetic analysis of 11 new breast cancer cell lines.";
Kallioniemi O.-P., Ethier S.P.
Br. J. Cancer 81:1328-1334(1999).
Constitutive activation of pp125fak in newly isolated human breast cancer cell lines.
Ignatoski K.M.W., Ethier S.P.
Breast Cancer Res. Treat. 54:173-182(1999).
Role of epidermal growth factor receptor and STAT-3 activation in autonomous proliferation of SUM-102PT human breast cancer cells.
Sartor C.I., Dziubinski M.L., Yu C.-L., Jove R., Ethier S.P.
Cancer Res. 57:978-987(1997).